Improving combination therapies: Targeting A2B adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. Jason V Evans , Shankar Suman , Mounika Uttam L Goruganthu , Elena E Tchekneva , Shuxiao Guan , Rajeswara Rao Arasada , Anneliese Antonucci , Longzhu Piao , Irina Ilgisonis , Andrey A Bobko , Benoit Driesschaert , Roman V Uzhachenko , Rebecca Hoyd , Alexandre Samouilov , Joseph Amann , Ruohan Wu , Lai Wei , Aaditya Pallerla , Sergey V Ryzhov , Igor Feoktistov , Kyungho P Park , Takefumi Kikuchi , Julio Castro , Alla V Ivanova , Thanigaivelan Kanagasabai , Dwight H Owen , Daniel J Spakowicz , Jay L Zweier , David P Carbone , Sergey V Novitskiy , Valery V Khramtsov , Anil Shanker , Mikhail M Dikov Journal of the National Cancer Institute（2023）
摘要
Data identify A2BAR as a valuable therapeutic target to modify metabolic and immune TME to reduce immunosuppression, enhance the efficacy of immunotherapies, and support clinical application of PBF-1129 in combination therapies.
更多 查看译文
AI 理解论文
溯源树
样例
